SNF4435C and D, novel immunosuppressants produced by a strain of
The emergence of multidrug resistance (MDR) is one of the major clinical problems in cancer chemotherapy. A well-known mechanism involved in this phenomenon is the overexpression of P-glycoprotein, the product of the mdr-1 gene in human cells. [1] [2] [3] P-Glycoprotein acts as an ATP-dependent, drug-transmembrane transporter that decreases intracellular accumulation of structurally and functionally unrelated anticancer agents. 4, 5) Since calcium channel blockers such as verapamil 6) and calmodulin inhibitors 7) were found to overcome MDR in vivo as well as in vitro, various MDR modifiers have been developed. [8] [9] [10] [11] [12] [13] Though some of them are undergoing clinical trials, 8, 9) their efficacy is not entirely satisfactory. Accordingly, more potent and less toxic modifiers are indispensable for clinical reversal of MDR.
SNF4435C and D are novel immunosuppressive agents isolated from the culture broth of a strain of Streptomyces spectabilis. 14, 15) The compounds are nitrophenyl pyrones having an intriguing tricyclic ring system and are diastereoisomers. Interestingly, SNF4435C and D selectively suppressed B-cell proliferation induced by lipopolysaccharide (LPS) versus T-cell proliferation induced by Con A in vitro. Several immunosuppressive agents 16, 17) reverse MDR by inhibiting the function of P-glycoprotein. We were therefore interested in the effect of these compounds on MDR tumor cells, and we found that the compounds are effective modifiers, overcoming MDR. In this report, we describe the potency of SNF4435C and D in conquering MDR tumor cells.
Animals Female CDF 1 mice were purchased from Charles River Japan, Inc. (Kanagawa). They were maintained under specific pathogen-free conditions at 23±2°C and 50±10% relative humidity. Lighting was automatic under a 12 h light/dark cycle. The mice were allowed free access to commercially available standard diet and water. All mice were 6 weeks old at the start of experiments. Tumor cells P388, VCR-resistant P388 (P388/VCR) and ADM-resistant P388 (P388/ADM) cell lines were supplied by the National Cancer Institute (NIH, Bethesda, MD). The K562 cell line was provided by Dr. Ezaki, Cancer Chemotherapy Center (Tokyo), and its VCR-resistant (K562/VCR) and ADM-resistant (K562/ADM) sublines were established in the Cancer Chemotherapy Center, Japanese Foundation for Cancer Research. 18, 19) The human ovarian cancer line A2780 and its ADM-resistant subline (AD 10 ) were provided by Drs. R. Ozols and T. Hamilton, Medicine Branch, NCI, NIH.
20)
Cell culture and drug treatment The tumor cells were cultured in RPMI-1640 medium (Life Technologies, Inc., Rockville, MD) supplemented with 10% fetal bovine serum (Life Technologies, Inc.), 100 µg/ml streptomycin sulfate (Meiji Seika Co., Ltd., Tokyo), 100 U/ml penicillin G (Meiji Seika Co., Ltd.) and 0.2% NaHCO 3 . For the culture of P388 and its sublines, 20 µM 2-mercaptoethanol was added to the above medium. 3 cells) in the exponential growth phase were suspended in 100 µl of culture medium and inoculated into 96-well flat-bottomed microplates. The plates were cultured at 37°C for 24 h (A2780 and AD 10 , which grow on the surface of the plate) or for 6 h (other cell lines, which grow in suspension) in a 5% CO 2 air atmosphere. The cells were then treated with graded concentrations of the indicated agent and reincubated in the CO 2 incubator at 37°C for 72 h. Three individual experiments were conducted at each agent concentration to confirm reproducibility. The colorimetric assay system (Cell Proliferation Kit I, Boehringer Mannheim GmbH, Mannheim, Germany) using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) was used for the quantification of in vitro chemosensitivity of tumor cells. 21) Cell growth was determined from the percentage ratio of optical density in agent-treated wells to that in non-treated wells. The median concentration of agent necessary to inhibit the growth of tumor cells by 50% (IC 50 ) was calculated from the dose-response curve.
Intracellular accumulation of [
3 H]VCR A2780 and AD 10 cells (10 6 cells) in the growth medium were seeded into 24-well plates and incubated at 37°C for 24 h in a 5% CO 2 air atmosphere. The medium in each well was aspirated and 0.5 ml of fresh culture medium containing 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid was added. Then [ 3 H]VCR (7.5 pmol) and the indicated concentrations of the agent were added to each well. After incubation at 37°C for 2 h, the intracellular accumulation of VCR was determined as described previously. 6, 7) In brief, the cells were washed twice with phosphate-buffered saline (PBS) and then treated with 0.1% sodium dodecyl sulfate (SDS)-0.2 N NaOH (0.15 ml/well) at 56°C for 60 min to solubilize the cells. The solution was transferred into a scintillant, ACSII (Amersham), and the radioactivity was counted by a liquid scintillation system (Beckman, LS9800, Fullerton, CA). Results are given for three independent experiments. Evaluation of antitumor activity P388 and P388/VCR cells (10 6 cells/mouse) were transplanted intraperitoneally (i.p.) into CDF 1 mice on day 0. VCR was dissolved in 0.9% NaCl solution and SNF4435C was suspended in 0.9% NaCl solution containing 20% HCO-60 (Nikko Chemicals Co., Ltd., Tokyo). The agents were administered i.p. daily for 5 consecutive days from 1 day after tumor inoculation, either independently or concurrently with VCR. In the in vivo study, the modifier SNF4435C was given at 6 h before injection of VCR. Six mice were used for each experimental group. Antitumor activity of the agents was evaluated in terms of the median survival of the experimental group and was expressed as the treated/control (T/C) value. (Tables I and II) was due to reversal of MDR, the cytotoxicity of SNF4435C and D on the tumor cells was tested (Fig. 2) . Although the dose-dependent inhibition curves varied among the unrelated cells, the dose-response curve of a MDR cell line was quite similar to that of its drug-sensitive parent cell line. In the presence of 30 µM SNF4435C and D, the growth rates of P388 and its variants, K562 and its variants, and A2780 and its variant were 46-55%, 35-41% and 10-18%, respectively. By contrast, SNF4435C and D at less than 10 µM had little influence on the cytotoxicity. Consequently, we considered that the evaluation of reversal of MDR was little affected by the cytotoxicity of SNF4435C and D. (Fig. 3) . In A2780 cells, the amount of accumulated [ 3 H]VCR was slightly increased by the addition of SNF4435C, D, FK506, CysA and verapamil. When FK506, CysA and verapamil were added to the assay solution, the amount of accumulated VCR in AD 10 cells significantly increased in a dose-dependent manner. Ten micromolar FK506, CysA and verapamil increased the accumulated VCR by more than 2-fold. Similar results were obtained by the addition of SNF4435C and D, and at 10 µM, the compounds enhanced the accumulation of VCR in AD 10 cells more potently than FK506, CysA and verapamil.
Effects of SNF4435C and D on the accumulation of VCR

Antitumor effect of SNF4435C in P388-bearing mice
The antitumor efficacy of SNF4435C was examined with the sensitive P388 leukemia model (Table III) . The admin- istration of SNF4435C (2.5-10 mg/kg) had no antitumoral effect in P388/sensitive-bearing mice (T/C values 96-107%). By contrast, administration of 0.2 mg/kg VCR showed good antitumoral activity (T/C=191%). Synergistic effect of VCR and SNF4435C on P388/ VCR-bearing mice The ability of SNF4435C to potentiate the antitumor activity of VCR in the drug-resistant P388/VCR leukemia model was investigated (Table IV) . The administration of SNF4435C alone at a dose range of 2.5-10 mg/kg scarcely altered the survival time as compared to the control group (T/C values 97-109%). The administration of 0.2 mg/kg VCR alone also exhibited only a modest chemotherapeutic effect (T/C=111%). However, the combination of SNF4435C and VCR increased the life span of P388/VCR-bearing mice in a dose-dependent manner. When 10 mg/kg SNF4435C was administered concurrently with 0.2 mg/kg VCR, the antitumor efficacy was significantly potentiated (T/C=143%) in comparison with the administration of either SNF4435C or VCR alone. No severe losses of body weight were observed with this combination.
DISCUSSION
SNF4435C and D are novel immunosuppressants having an intriguing tricyclic ring system. 15) The compounds potently suppress B-cell proliferation induced by LPS versus T-cell proliferation induced by Con A.
14) The mechanism involved in the immunosuppressive action of SNF4435C and D is clearly different from that of CysA and FK506, which suppress the immune system by blocking T-cell activation. We found that SNF4435C and D were also effective in overcoming MDR, like CysA and FK506. The resistance to VCR in P388/VCR, P388/ ADM, K562/VCR, K562/ADM and AD 10 cells in vitro was completely reversed by SNF4435C and D, in an almost nontoxic dose range. Furthermore, SNF4435C and D moderately enhanced the sensitivity of the MDR cells to ADM, though the reversal was not complete. The accumulation of VCR in drug-resistant AD 10 cells was increased by SNF4435C and D as effectively as by verapamil, CysA and FK506, while these compounds had no effect on the accumulation of VCR in the drug-sensitive parental A2780 cells. From these results, it is likely that the mechanism involved in the action of SNF4435C and D in overcoming MDR is similar to that of verapamil, CysA and FK506. It was found that those drugs are modulators of cellular Pglycoprotein via direct binding, leading to inhibition of the pump activity. 22, 23) Alternatively, other unknown mechanisms may be involved in the action, because SNF4435C and D significanlly potentiated the cytotoxicity of VCR towards drug-sensitive parental P388 cells. In vivo, SNF4435C was also effective in overcoming VCR resistance. When 10 mg/kg SNF4435C was concomitantly administered with 0.2 mg/kg VCR, the chemotherapeutic effect of VCR in P388/VCR-bearing mice was potentiated by 143% (T/C). The dosage of SNF4435C for overcoming the resistance in P388/VCR-bearing mice was almost the same as that exhibiting suppression of graft rejection (data not shown). The immunosuppressive activity might limit the clinical use of SNF4435C and D for conquering MDR. Considering the possible direct interaction between SNF4435C or D and P-glycoprotein, the reversing activity is not likely to be related to the immunosuppressive activity. Through studies of cyclosporins, non-immunosuppressive analogues of CysA that exhibit MDR modifying activity have been developed. 8, 24) Accordingly, exploration and development of non-immunosuppressive SNF4435 derivatives might provide promising agents for cancer chemotherapy. 
